We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down
Read MoreHide Full Article
QIAGEN N.V.’s (QGEN - Free Report) fourth-quarter 2022 adjusted earnings per share (EPS) were 53 cents (55 cents at constant exchange rate or CER), down 28% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 12.8%.
The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses and purchased intangibles amortization expenses, among others.
GAAP EPS for the quarter was 36 cents per share, down 30% year over year.
For the full year, adjusted earnings were $2.38 per share, down 10% from the year-ago period’s levels. The figure, however, surpassed the Zacks Consensus Estimate by 12.3%.
Revenues in Detail
Net sales in the fourth quarter fell 14.5% year over year to $497.9 million (down 9% year over year at CER). The top line exceeded the Zacks Consensus Estimate by 3.6%. Sales at CER were $531 million, above the fourth quarter outlook of at least $520 million.
The fourth-quarter sales were driven by 15% CER growth in the non-COVID-19 portfolio to $432 million. However, sales of COVID-19 products plunged 61% at CER to $66 million amid significantly reduced demand.
Total revenues for 2022 were $2.14 billion, up 4.9% from the year-ago period’s levels. The figure lagged the Zacks Consensus Estimate by 7.8%.
Geographical Revenue Update
In the quarter under review, sales from the Americas (48% of sales) totaled $241 million, up 7% reportedly (down 6% at CER).
Revenues from Europe, the Middle East and Africa (34% of sales) fell 23% reportedly (down 13% at CER) to $169 million.
Further, revenues from Asia-Pacific/Japan (18% of sales) fell 16% year over year on a reported basis (down 6% at CER) to $88 million.
Segmental Details
As of the fourth quarter of 2022, QIAGEN had two major customer classes – Molecular Diagnostics and Life Sciences.
Molecular Diagnostics (representing 51.5% of net sales) revenues were down 18% on a reported basis (down 12% at CER) to $258 million.
Life Sciences (48.5% of total revenues) reported revenues of $240 million, down 11% on a reported basis (down 5% at CER).
Operational Update
Adjusted gross profit in the quarter under review fell 14.6% to $332.5 million. Meanwhile, the adjusted gross margin contracted 6 basis points (bps) to 66.8% on a 14.3% rise in the total cost of sales (adjusting for acquisition-related intangible amortization) to $165.5 million.
Sales and marketing expenses of QIAGEN rose 2.4% to $122.2 million year over year. Research and development expenses rose 6.2% year over year to $44.7 million, whereas general and administrative expenses fell 2.8% year over year to $31.9 million.
Adjusted operating income (excluding items like acquisition-related intangible amortization, restructuring and integration and asset impairment) declined 31.4% year over year to $133.5 million in the fourth quarter. Meanwhile, the adjusted operating margin contracted 663 bps to 26.8%.
Financial Update
QIAGEN exited 2022 with cash and cash equivalents and short-term investments of $1.42 billion, up from $1.07 billion at the end of 2021. Long-term debt was $1.47 billion at the end of 2022 compared with $1.09 at the end of 2021.
Cumulative net cash flow from operating activities at the end of 2022 was $715.3 million compared with $639 million in the year-ago period.
Guidance
QIAGEN has initiated its outlook for 2023.
Full-year net sales are expected to be about $2.05 billion at CER. The Zacks Consensus Estimate for the metric is pegged at $2.04 billion.
Adjusted EPS for 2023 is expected to be about $2.10 at CER. The Zacks Consensus Estimate for adjusted EPS is pegged at $2.09.
For the first quarter of 2023, the company expects net sales to be at least $490 million at CER. The Zacks Consensus Estimate for the same is pegged at $493.5 million.
Adjusted EPS is expected to be at least 47 cents at CER. The Zacks Consensus Estimate for adjusted EPS is pegged at 48 cents.
Our Take
QIAGEN ended fourth-quarter 2022 with better-than-expected earnings and revenues. However, on a year-over-year basis, earnings and sales both declined. The massive decline in COVID-19 product sales and severe foreign exchange headwind impacted overall performance. Escalating costs and the contraction of gross margin operating margin is a concern.
On a positive note, the ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides. The QIAcuity digital PCR system delivered solid double-digit CER growth for fiscal 2022, supported by the launch of new assays for biopharma applications. Further, QuantiFERON-TB also registered a solid double-digit CER growth in 2022, led by continued conversion of the latent TB market from the traditional skin test.
Zacks Rank and Other Key Picks
QIAGEN currently carries Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Neogen Corporation (NEOG - Free Report) , McKesson Corporation (MCK - Free Report) and Hologic, Inc. (HOLX - Free Report) .
Neogen, carrying a Zacks Rank #2, reported second-quarter fiscal 2023 adjusted EPS of 15 cents, beating the Zacks Consensus Estimate of loss of 8 cents per share. Revenues of $230 million outpaced the consensus mark by 0.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Neogen has an earnings yield of 2.5% compared with the industry’s 0.2%. NEOG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in two, the average being 70.11%.
McKesson, having a Zacks Rank #2, reported third-quarter 2023 adjusted EPS of $6.90, which beat the Zacks Consensus Estimate by 8.8%. Revenues of $70.49 billion outpaced the consensus mark by 0.02%.
McKesson has a long-term estimated growth rate of 10.1%. MCK’s earnings surpassed estimates in two of the trailing four quarters and missed the same in two, the average being 4.79%.
Hologic reported first-quarter 2023 adjusted earnings of $1.07 per share, beating the Zacks Consensus Estimate by 18.9%. Revenues of $1.07 billion surpassed the Zacks Consensus Estimate by 9.5%. It currently sports a Zacks Rank #1.
Hologic has a long-term estimated growth rate of 15.2%. HOLX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 46.08%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down
QIAGEN N.V.’s (QGEN - Free Report) fourth-quarter 2022 adjusted earnings per share (EPS) were 53 cents (55 cents at constant exchange rate or CER), down 28% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 12.8%.
The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses and purchased intangibles amortization expenses, among others.
GAAP EPS for the quarter was 36 cents per share, down 30% year over year.
For the full year, adjusted earnings were $2.38 per share, down 10% from the year-ago period’s levels. The figure, however, surpassed the Zacks Consensus Estimate by 12.3%.
Revenues in Detail
Net sales in the fourth quarter fell 14.5% year over year to $497.9 million (down 9% year over year at CER). The top line exceeded the Zacks Consensus Estimate by 3.6%. Sales at CER were $531 million, above the fourth quarter outlook of at least $520 million.
The fourth-quarter sales were driven by 15% CER growth in the non-COVID-19 portfolio to $432 million. However, sales of COVID-19 products plunged 61% at CER to $66 million amid significantly reduced demand.
Total revenues for 2022 were $2.14 billion, up 4.9% from the year-ago period’s levels. The figure lagged the Zacks Consensus Estimate by 7.8%.
Geographical Revenue Update
In the quarter under review, sales from the Americas (48% of sales) totaled $241 million, up 7% reportedly (down 6% at CER).
Revenues from Europe, the Middle East and Africa (34% of sales) fell 23% reportedly (down 13% at CER) to $169 million.
QIAGEN N.V. Price and EPS Surprise
QIAGEN N.V. price-eps-surprise | QIAGEN N.V. Quote
Further, revenues from Asia-Pacific/Japan (18% of sales) fell 16% year over year on a reported basis (down 6% at CER) to $88 million.
Segmental Details
As of the fourth quarter of 2022, QIAGEN had two major customer classes – Molecular Diagnostics and Life Sciences.
Molecular Diagnostics (representing 51.5% of net sales) revenues were down 18% on a reported basis (down 12% at CER) to $258 million.
Life Sciences (48.5% of total revenues) reported revenues of $240 million, down 11% on a reported basis (down 5% at CER).
Operational Update
Adjusted gross profit in the quarter under review fell 14.6% to $332.5 million. Meanwhile, the adjusted gross margin contracted 6 basis points (bps) to 66.8% on a 14.3% rise in the total cost of sales (adjusting for acquisition-related intangible amortization) to $165.5 million.
Sales and marketing expenses of QIAGEN rose 2.4% to $122.2 million year over year. Research and development expenses rose 6.2% year over year to $44.7 million, whereas general and administrative expenses fell 2.8% year over year to $31.9 million.
Adjusted operating income (excluding items like acquisition-related intangible amortization, restructuring and integration and asset impairment) declined 31.4% year over year to $133.5 million in the fourth quarter. Meanwhile, the adjusted operating margin contracted 663 bps to 26.8%.
Financial Update
QIAGEN exited 2022 with cash and cash equivalents and short-term investments of $1.42 billion, up from $1.07 billion at the end of 2021. Long-term debt was $1.47 billion at the end of 2022 compared with $1.09 at the end of 2021.
Cumulative net cash flow from operating activities at the end of 2022 was $715.3 million compared with $639 million in the year-ago period.
Guidance
QIAGEN has initiated its outlook for 2023.
Full-year net sales are expected to be about $2.05 billion at CER. The Zacks Consensus Estimate for the metric is pegged at $2.04 billion.
Adjusted EPS for 2023 is expected to be about $2.10 at CER. The Zacks Consensus Estimate for adjusted EPS is pegged at $2.09.
For the first quarter of 2023, the company expects net sales to be at least $490 million at CER. The Zacks Consensus Estimate for the same is pegged at $493.5 million.
Adjusted EPS is expected to be at least 47 cents at CER. The Zacks Consensus Estimate for adjusted EPS is pegged at 48 cents.
Our Take
QIAGEN ended fourth-quarter 2022 with better-than-expected earnings and revenues. However, on a year-over-year basis, earnings and sales both declined. The massive decline in COVID-19 product sales and severe foreign exchange headwind impacted overall performance. Escalating costs and the contraction of gross margin operating margin is a concern.
On a positive note, the ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides. The QIAcuity digital PCR system delivered solid double-digit CER growth for fiscal 2022, supported by the launch of new assays for biopharma applications. Further, QuantiFERON-TB also registered a solid double-digit CER growth in 2022, led by continued conversion of the latent TB market from the traditional skin test.
Zacks Rank and Other Key Picks
QIAGEN currently carries Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Neogen Corporation (NEOG - Free Report) , McKesson Corporation (MCK - Free Report) and Hologic, Inc. (HOLX - Free Report) .
Neogen, carrying a Zacks Rank #2, reported second-quarter fiscal 2023 adjusted EPS of 15 cents, beating the Zacks Consensus Estimate of loss of 8 cents per share. Revenues of $230 million outpaced the consensus mark by 0.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Neogen has an earnings yield of 2.5% compared with the industry’s 0.2%. NEOG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in two, the average being 70.11%.
McKesson, having a Zacks Rank #2, reported third-quarter 2023 adjusted EPS of $6.90, which beat the Zacks Consensus Estimate by 8.8%. Revenues of $70.49 billion outpaced the consensus mark by 0.02%.
McKesson has a long-term estimated growth rate of 10.1%. MCK’s earnings surpassed estimates in two of the trailing four quarters and missed the same in two, the average being 4.79%.
Hologic reported first-quarter 2023 adjusted earnings of $1.07 per share, beating the Zacks Consensus Estimate by 18.9%. Revenues of $1.07 billion surpassed the Zacks Consensus Estimate by 9.5%. It currently sports a Zacks Rank #1.
Hologic has a long-term estimated growth rate of 15.2%. HOLX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 46.08%.